Navigation Links
Baxter Announces Licensing Agreement for Innocoll's Gentamicin Surgical Implant in the United States
Date:8/25/2008

The antibiotic surgical product may reduce incidence of surgical site

infections and reduce post-operative cost and complications

DEERFIELD, Ill. and ASHBURN, Va., Aug. 25 /PRNewswire-FirstCall/ -- Baxter Healthcare Corporation today announced a licensing agreement with Innocoll Pharmaceuticals Ltd, a division of Innocoll, Inc., granting Baxter exclusive rights to market and distribute the company's gentamicin surgical implant in the United States. The gentamicin surgical implant will be the first and only biodegradable, leave-behind antibiotic surgical sponge used as an adjunct (add-on) therapy for prevention and treatment of surgical site infections (SSIs) in the United States. This agreement is expected to add to Baxter's biosurgical portfolio by giving surgeons an innovative option to help reduce risk of post-operative complications of SSIs during surgery.

The collagen-based implant is saturated with a high concentration of an antibiotic, gentamicin, designed to deliver the antibiotic directly to the target tissue while maintaining low levels of the drug in order to potentially reduce infection during and after surgery. The gentamicin surgical implant is fully biodegradable and can be left in the body after surgery. According to the Centers for Disease Control and Prevention, SSIs remain an ongoing problem for surgeons and are a burden on patients and the healthcare system, affecting more that 500,000 patients a year in the United States.

The product was developed using Innocoll's proprietary, collagen-based drug delivery technology, CollaRx, and is indicated outside of the United States as an adjunct to systemic antibiotic therapy for the treatment of localized, deep tissue infections and the prevention of SSIs in both hard and soft tissues.

The implant is approved in 49 countries spanning Europe, Latin America, the Middle East, Africa and Asia. It is currently in two Phase III clinical trials in the United States to
'/>"/>

SOURCE Baxter Healthcare Corporation
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. Baxter Declares Quarterly Dividend
2. Baxter Raises Full-Year 2008 Outlook Following Strong Second-Quarter Financial Results
3. Bioniche Pharma Acquires Baxters ENLON(R) and ENLON-PLUS(R)
4. Baxters Board of Directors Declares Quarterly Dividend
5. Baxter Reports Solid First Quarter Financial Results and Raises Full-Year Outlook
6. Baxters V-Link Luer-Activated Device With VitalShield Protective Coating Now Available For Hospitals
7. Baxter Announces FDA Approval of ARTISS Slow-Setting Fibrin Sealant in Treatment of Burn Patients
8. Baxters Board of Directors Approves New Share Repurchase Authorization of $2 Billion
9. Baxter and Its Foundation Contribute Nearly $53 Million in 2007 to Address Critical Needs Locally and Globally
10. Baxter to Proceed With Recall of Remaining Heparin Sodium Vial Products
11. Baxter Declares Quarterly Dividend

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)... BOCA RATON, Fla., Nov. 25 For man... for BodyLogicMD. The nation,s largest and fastes...g exclusively in medically supervised bioidentica... in its network since November 2008 - from 21 t...physician-owned centers, including one in Puerto R...
(Date:11/25/2009)...25 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. ( SVA...nnounced today that it executed,a joint venture (J...,Technology Co., Ltd. (Sinovac Dalian). The JV wil...an-use vaccines. Sinovac will contribute its exper...ing world-class vaccines; the,other party will bri...
(Date:11/25/2009)...wswire-FirstCall/ -- Ardea Biosciences, Inc. (Nasd...harm.D., president and chief executive officer, wi... Care Conference. , ,Presentation details are as ...nference,Date: Tuesday, December 1, 2009,Time...ork Palace Hotel, New York, NY,Webcast: <a href...
(Date:11/24/2009)...ewswire-FirstCall/ -- IES (Nasdaq: IESC ), a lead...ions systems and services for the commercial, indu...at its commercial business group has been awarded ... electrical systems for the Level 4 bio-safety lab...ical Research Institute of Infectious Diseases (US...
Breaking Biology Technology:Nation's Largest Network of Doctors Specializing in Bioidentical Hormones Grows at an Exponential Rate 2Nation's Largest Network of Doctors Specializing in Bioidentical Hormones Grows at an Exponential Rate 3Nation's Largest Network of Doctors Specializing in Bioidentical Hormones Grows at an Exponential Rate 4Sinovac Establishes Joint Venture to Expand Human-Use Vaccine Development and Manufacturing Capabilities 2Sinovac Establishes Joint Venture to Expand Human-Use Vaccine Development and Manufacturing Capabilities 3Ardea Biosciences to Present at the Piper Jaffray 21st Annual Health Care Conference 2Integrated Electrical Services Awarded Contract to Provide Electrical Systems for U.S. Army Medical Research Institute of Infectious Diseases 2
...eduled for Wednesday, July 30, SAN DIEGO, July 23...ounced today that the Company will report its seco... market closes on Wednesday,July 30, 2008. Neurocr...o,discuss its financial results and provide a Comp...:00 p.m. Eastern Time (2:00 p.m. Pacific,Time)., ...
...RNewswire-FirstCall/ - Chromos Molecular,Systems I...hat the,securities commissions or similar regulato...a, Alberta, Manitoba, Ontario and Quebec have revo...ective July 22, 2008. As a,result, there are curre...,Company., The Company continues to review its re...
...ge Technologies, Inc.,(BST) will serve as the bior...na Health Study, a new landmark longitudinal study...research initiative will utilize the,population of...cipants and,will enable research that will lead to...etter manage common, chronic diseases such as hear...
Other Biology Technology:Neurocrine Biosciences Announces Conference Call and Webcast To Present Second Quarter 2008 Financial Results 2Chromos Announces Full Revocation of Cease Trade Orders 2BioStorage Technologies Serves as Repository for Landmark Study of Coronary Artery Disease 2
(Date:11/24/2009)...day named 12 new grant recipients for 2009. The aw...work across a broad spectrum of lupus research. Al... potential to drive scientific discovery to ultima...of systemic lupus. , The 2009 grants go to both ...ation and include interdisciplinary and highly pro...
(Date:11/24/2009)...Medical Toxicology (ACMT) have signed an agreement... of Medical Toxicology (JMT), the official journa...eviously published by the University of Pennsylvan..., an international, peer-reviewed journal, is dedi...ical toxicology. The quarterly journal focuses on...
(Date:11/24/2009)...h . , The presence of increased body fat, an...es in the blood, hinders the loss and maintenance ...the University of Navarra conducted by Estbaliz Go...cy. , The project, entitled "A nutrigenetic and ...ody weight and inflammation," examines how the ind...
Breaking Biology News(10 mins):Lupus Research Institute announces 2009 novel research grants 2Lupus Research Institute announces 2009 novel research grants 3Springer and the American College of Medical Toxicology to work together 2It can be predicted the reaction obese patients will have to a diet 2Clarient Set to Join Russell 3000 Index 50245 1Clarient Set to Join Russell 3000 Index 50245 2Clarient Set to Join Russell 3000 Index 50245 3Clarient Set to Join Russell 3000 Index 50245 4Video 3A New Online Film Introduces Longevinex Advantage 28TM 29 The First Resveratrol Based Dietary Supplement to Address Both Cellular and Connec 50244 1Video 3A New Online Film Introduces Longevinex Advantage 28TM 29 The First Resveratrol Based Dietary Supplement to Address Both Cellular and Connec 50244 2Proactive Pet Care Essential in Low Cash Times Says NOAH 50241 1Proactive Pet Care Essential in Low Cash Times Says NOAH 50241 2Proactive Pet Care Essential in Low Cash Times Says NOAH 50241 3
...esearchers have suspected there must be a natural ...body and could be harnessed to develop more effect...or hypertension. Currently, drugs that lower sodiu...y also reduce potassium levels., Researchers at Co...esearch (BTI) have used a new technique and identi...
...g an effort to eradicate malaria, the mosquito-bor... every year" Researchers at the National Institute...ertise in radiation science to help a young compan...a-causing parasite. These parasites, in turn, are ...ows promise of being more effective than current m...
...AND HYBRID-POWERED VEHICLES CAN PROVIDE MORE SOCIE...ght trucks powered by advanced diesel technology o...nefits than traditional gasoline-powered automobil...presented today. , The research by RAND, a non-pr...trucks and cars continuously fueled by a mixture o...
Other Biology News:Researchers' discovery may lead to hypertension treatment 2Bug-Zapper: A dose of radiation may help knock out malaria 2RAND paper finds diesel, hybrid vehicles can provide more societal benefits than gas-powered autos 2RAND paper finds diesel, hybrid vehicles can provide more societal benefits than gas-powered autos 3RAND paper finds diesel, hybrid vehicles can provide more societal benefits than gas-powered autos 4
DNase I, RNase-free; special quality for molecular biology from Roche Applied Science
RQ1 RNase-Free DNase from Promega
... DNA Polymerase I catalyzes the template-directed ... 5?3 direction. DNA Polymerase I possesses a 3?5 e...ich lowers the error rate during DNA replication, ...h enables the enzyme to replace nucleotides in the...
RNase-Free Dnase from BD Biosciences Pharmingen
Biology Products: